Adding pegylated interferon-α to nucleos(t)ide analogs improves HBsAg clearance in chronic hepatitis B with low-level viremia

Adding pegylated interferon-α to nucleos(t)ide analogs improves HBsAg clearance in chronic hepatitis B with low-level viremia

IntroductionLow-level viremia (LLV) is associated with the progression of liver fibrosis and a high risk of hepatocellular carcinoma in patients with chronic hepatitis B (CHB). The present study aimed to compare the efficacy between nucleos(t)ide analogs (NAs) therapy and combination therapy of NAs...

Full description

Saved in:

Bibliographic Details
Main Authors:	Lilin Wang, Junfeng Lu, Dan Liu, Shan Ren, Xinyue Chen, Zhongjie Hu, Sujun Zheng
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-08-01
Series:	Frontiers in Medicine
Subjects:	low-level viremia chronic hepatitis B pegylated interferon-α tenofovir alafenamide fumarate HBsAg clearance
Online Access:	https://www.frontiersin.org/articles/10.3389/fmed.2025.1642961/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Discussion on the duration of response following HBsAg clearance in patients with chronic hepatitis B treated with PegIFNα-2b
by: Tao Wang, et al.
Published: (2025-04-01)

Unexpected rise in the circulation of complex HBV variants enriched of HBsAg vaccine-escape mutations in HBV genotype-D: potential impact on HBsAg detection/quantification and vaccination strategies
by: Lorenzo Piermatteo, et al.
Published: (2023-12-01)

Predictors of HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients treated with nucleotide analogs plus polyethylene glycol interferon
by: Yan Peng, et al.
Published: (2025-01-01)

HBsAg and anti-HBs coexistence in patients with HBV in acute and chronic phases
by: Zhongshu Pu, et al.
Published: (2025-05-01)

Metabolic Outcomes of Changing From Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine to Rilpivirine/Tenofovir Alafenamide/Emtricitabine: A Longitudinal Study
by: Ping‐Feng Wu, et al.
Published: (2024-12-01)

Hepatitis surface B antigen clearance induced by long-term tenofovir disoproxil fumarate monotherapy in chronic hepatitis B treatment: a meta-analysis and longitudinal modeling analysis
by: Weizhe Jian, et al.
Published: (2025-05-01)

Predicting relapse after achieving a functional cure for chronic hepatitis B (CHB) using baseline HBsAg and end-of-treatment HBsAb levels
by: Lianxiu Han, et al.
Published: (2025-04-01)

基因工程乙肝疫苗的研制——Ⅲ.MT-5细胞的HBsAg纯化与鉴定
Published: (1990-01-01)

Effects of folic acid supplementation before conception on innate immunity and anti-HBs levels of offspring born to HBsAg-positive mothers
by: Jia Lian, et al.
Published: (2025-04-01)

Efficacy of extracorporeal immunoadsorption therapy for removal of HBsAg
by: Meng Wang, et al.
Published: (2025-07-01)

Factors driving decisions in the use of HIV pre-exposure prophylaxis: a real-world study in the United States
by: Yohance Whiteside, et al.
Published: (2024-12-01)

Hepatitis B vaccination in Burkina Faso: prevalence of HBsAg carriage and immune response in children in the western region
by: Armel Moumouni Sanou, et al.
Published: (2018-11-01)

The presence of baseline HBsAb-Specific B cells can predict HBsAg or HBeAg seroconversion of chronic hepatitis B on treatment
by: Shengxia Yin, et al.
Published: (2023-12-01)

Advanced Liver Disease Events in People with HIV and Hepatitis B Virus Coinfection Initiating Antiretroviral Therapy in the United States
by: Ching-Yi Chuo, et al.
Published: (2025-07-01)

Prediction of long-term HBsAg seroclearance in patients with HBeAg-negative chronic hepatitis B
by: Hae Lim Lee, et al.
Published: (2025-07-01)

Rapid suppression of HBV replication before related liver transplantation in a patient with HDV superinfection. Clinical case report
by: U. R. Salimov, et al.
Published: (2024-09-01)

慢性HBV 感染者血清HBsAg 自发转阴的影响因素分析
by: 陈兴, et al.
Published: (2018-01-01)

Steatosis and Interferon Associated with HBsAg Immune Control in Chronic Hepatitis B: A Real-World Propensity Score-Matched Study
by: Qi Xu, et al.
Published: (2025-06-01)

Comparison of lipid profile alterations in chronic hepatitis b patients receiving tenofovir alafenamide or tenofovir disoproxil fumarate
by: Shenglong Lin, et al.
Published: (2024-11-01)

High HBsAg clearance rate and viral dynamics in HBeAg-positive, ALT-normal children and adolescents with chronic HBV infection: results from the prospective sprout project
by: Xin Wang, et al.
Published: (2025-12-01)

Quantitative dynamic evaluation HBsAg in blood in comparison to viral load level in patients with chronic HBV-monoinfection
by: K. R. Dudina, et al.
Published: (2011-06-01)

Reevaluating antiviral thresholds in HBV DNA-negative inactive HBsAg carriers: a multicenter histopathological analysis
by: Shan Ren, et al.
Published: (2025-07-01)

HBsAg clearance and seroconversion case in a patient with HBeAg-negative chronic hepatitis B on pegylated interferon α-2a therapy
by: K. V. Zhdanov, et al.
Published: (2014-09-01)

慢性HBV感染者核苷（酸）类似物长期治疗HBsAg转阴的影响因素
by: 李向永, et al.
Published: (2018-01-01)

Prevalence of HBsAg among Moroccan HIV-1 infected patients and APOBEC3G variant frequencies in HIV-1/HBV co-infection
by: Imane Belbacha, et al.
Published: (2024-05-01)

Outcomes of switching from protease inhibitor-based antiretroviral therapy to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed adults with nucleos(t)ide analogue resistance– a phase IV randomised, open-label study (PIBIK study)
by: Collins Iwuji, et al.
Published: (2025-02-01)

Effect of potent nucleos(t)ide analog on alpha fetoprotein changes and occurrence of hepatocellular carcinoma in patients with chronic hepatitis B
by: Qianqian Ma, et al.
Published: (2025-02-01)

Erişkin HBsAg Pozitif Hastalarda Hepatit A Seroprevalansı
by: Alper Tahmaz, et al.
Published: (2020-09-01)

A predictive model for functional cure in chronic HBV patients treated with pegylated interferon alpha: a comparative study of multiple algorithms based on clinical data
by: Ya-mei Ye, et al.
Published: (2024-12-01)

Development of Low-Cost In-House Assays for Quantitative Detection of HBsAg, HBeAg, and HBV DNA to Enhance Hepatitis B Virus Diagnostics and Antiviral Screening in Resource-Limited Settings
by: Simmone D’souza, et al.
Published: (2025-03-01)

Neutrophils-mediated accelerated blood clearance phenomenon in beagles and rats based on the cross-injection of non-PEGylated and PEGylated nanoemulsions
by: Mengyang Liu, et al.
Published: (2025-06-01)

慢性HBV感染者经核苷（酸）类似物治疗获血清HBsAg 转阴后的长期预后
by: 崇雨田, et al.
Published: (2018-01-01)

Exploring using HBsAg to predict interferon treatment course to achieve clinical cure in chronic hepatitis B patients: a clinical study
by: Fei Yan, et al.
Published: (2025-01-01)

Protracted HBsAg-aemia in a Patient with Acute Hepatitis B
by: K. R. Dudina, et al.
Published: (2018-11-01)

The influence of different detection cycles on the detection results of HBsAg ELISA
by: DENG Yanqing, et al.
Published: (2024-11-01)

Trend in seroprevalence of Hepatitis B virus infection among blood donors of coastal Karnataka, India
by: Karandeep Singh, et al.
Published: (2009-06-01)

Synthesis and Evaluation of Anti-HIV Activity of Mono- and Di-Substituted Phosphonamidate Conjugates of Tenofovir
by: Aaminat Qureshi, et al.
Published: (2022-07-01)

Improvement in renal function after switching from entecavir to tenofovir alafenamide in chronic hepatitis B patients with low estimated glomerular filtration rates
by: Liang Wang, et al.
Published: (2025-07-01)

Kan vericilerde HBsAg, anti-HCV, anti-HIV ve Sifilis seroprevalansı
by: Mustafa Altındiş, et al.
Published: (2011-03-01)

Clinical laboratory characteristic of hospitalized patients with HBsAg negative chronic hepatitis B
by: E. O. Shibaeva, et al.
Published: (2014-09-01)